Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
These Markers Can Categorize Risk in AML Patients
Cancer; ePub 2017 Feb 21; Qu, Othus, et al
Two methylation markers appear to accurately categorize risk in patients with acute myeloid leukemia (AML) with normal karyotype (NK), according to an analysis of 7 SWOG trials.
Investigators used the so-called “CHARMcox” approach in a phase 1 cohort (n=72). They then applied bisulfite pyrosequencing to evaluate survival-associated methylation regions (SAMRs) in phase 2 model-building (n=65) and phase 3 validation (n=65) cohorts. Results were further validated in an independent external cohort (n=93). Among the results:
- Two SAMRs, LZTS2 and NR6A1, were identified.
- Hypomethylation of either of these SAMRs was linked with worse overall survival in the SWOG cohort.
- The prognosis was validated in patients with AML-NK from the independent cohort.
- Methylation values below the median at both markers predicted worse overall survival in both the SWOG and independent cohorts.
Qu X, Othus M, Davison J, et al. Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. [Published online ahead of print February 21, 2017]. Cancer. doi:10.1002/cncr.30626.